Skip to main content
SpringerLink
Log in

Delamanid in multidrug-resistant tuberculosis: a guide to its use in the EU

  • Adis Drug Q&A
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Oral delamanid (Deltyba®) is a useful addition to the treatment options currently available to treat patients with multidrug-resistant tuberculosis (MDR-TB). In the EU, it is indicated for use as part of an appropriate combination regimen in adults with MDR-TB when an effective treatment regimen cannot otherwise be composed due to resistance or tolerability. It exhibits potent antitubercular activity against drug-susceptible and -resistant strains of Mycobacterium tuberculosis. In a 3-month randomized control trial (2 months treatment + 1 month follow-up) in adults with MDR-TB, delamanid 100 mg twice daily + an optimized background regimen (OBR) improved 2-month sputum culture conversion rates to a significantly greater extent than placebo + OBR. In consecutive extension and follow-up studies, treatment with delamanid for ≥6 to 8 months was associated with higher rates of favourable outcomes and lower rates of unfavourable outcomes than treatment for ≤2 months. Delamanid was generally well tolerated in patients with MDR-TB. To reduce the potential risk of QT interval prolongation with delamanid, recommendations regarding monitoring and precautionary measures should be followed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Lange C, Abubakar I, Alffenaar JW, et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J. 2014;44(1):23–63.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Global tuberculosis report 2014. Geneva: World Health Organization; 2014.

  3. Zumla AI, Gillespie SH, Hoelscher M, et al. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis. 2014;14(4):327–40.

    Article  CAS  PubMed  Google Scholar 

  4. Matteelli A, Roggi A, Carvalho ACC. Extensively drug-resistant tuberculosis: epidemiology and management. Clin Epidemiol. 2014;6(1):111–8.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Sotgiu G, Migliori GB. Facing multi-drug resistant tuberculosis. Pulm Pharmacol Ther. 2015;32:144–8.

    Article  CAS  PubMed  Google Scholar 

  6. Olaru ID, von Groote-Bidlingmaier F, Heychendorf J, et al. Novel drugs against tuberculosis: a clinician’s perspective. Eur Respir J. 2015;45(4):1119–31.

    Article  CAS  PubMed  Google Scholar 

  7. Deltyba (delamanid) 50 mg film-coated tablets: summary of product characteristics. London: European Medicines Agency; 2014.

  8. Deltyba (delamanid): public assessment report. London: European Medicines Agency; 2014.

  9. Hurdle JG, Lee RB, Budha NR, et al. A microbiological assessment of novel nitrofuranylamides as anti-tuberculosis agents. J Antimicrob Chemother. 2008;62(5):1037–45.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Matsumoto M, Hashizume H, Tomishige T, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006;3(11):e466.

    Article  PubMed Central  PubMed  Google Scholar 

  11. Shimokawa Y, Sasahara K, Yoda N, et al. Delamanid does not inhibit or induce cytochrome p450 enzymes in vitro. Biol Pharm Bull. 2014;37(11):1727–35.

    Article  CAS  PubMed  Google Scholar 

  12. Gler MT, Skripconoka V, Sanchez-Garavito E, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med. 2012;366(23):2151–60.

    Article  CAS  PubMed  Google Scholar 

  13. Skripconoka V, Danilovits M, Pehme L, et al. Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J. 2013;41(6):1393–400.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Wells CD, Gupta R, Hittel N, et al. Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid. Eur Respir J. 2015;45(5):1498–501.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Gupta R, Geiter LJ, Wells CD, et al. Delamanid for extensively drug-resistant tuberculosis. New Engl J Med. 2015;373(3):291–2.

    Article  PubMed  Google Scholar 

  16. Shimokawa Y, Sasahara K, Koyama N, et al. Metabolic mechanism of delamanid, a new anti-tuberculosis drug, in human plasma. Drug Metab Dispos. 2015;43(8):1277–83.

    Article  CAS  PubMed  Google Scholar 

  17. Sasahara K, Shimokawa Y, Hirao Y, et al. Pharmacokinetics and metabolism of delamanid, a novel anti-tuberculosis drug, in animals and humans; importance of albumin metabolism in vivo. Drug Metab Dispos. 2015;43(8):1267–76.

    Article  CAS  PubMed  Google Scholar 

  18. The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance. Geneva: World Health Organization; 2014.

  19. Brigden G, Nyang’wa B-T, du Cros P, et al. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ. 2014;92(1):68–74.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Diacon AH, Von Groote-Bidlingmaier F, Donald PR. Delamanid, a new 6-nitro-2,3-dihydroimidazo[2,1-b]oxazole for the management of tuberculosis resistant to at least isoniazid and rifampicin. Expert Opin Orphan Drugs. 2014;2(1):87–94.

    Article  CAS  Google Scholar 

  21. US National Institutes of Health. ClinicalTrials.gov. 2015. http://www.clinicaltrials.gov/. Accessed 23 Sep 2015.

  22. Wang H, Zhang X, Bai Y, et al. Comparative efficacy and acceptability of five anti-tubercular drugs in tretament of multidrug resistant tuberculosis: a network meta-analysis. J Clin Bioinforma. 2015;5:5.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Lessem E, Cox H, Daniels C, et al. Access to new medications for the treatment of drug-resistant tuberculosis: patient, provider and community perspectives. In J Infect Dis. 2015;32:56–60.

    Google Scholar 

  24. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2014.

  25. Hafkin J, Frias M, Hesseling A, et al. Pharmacokinetics and safety of delamanid in children ages 6–17 years with MDR TP [poster no. A-960]. In: Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC)/International Congress of Chemotherapy and Infection (ICC); 2015.

  26. Diel R, Hittlel N, Schaberg T. Cost effectiveness of treating multi-drug resistant tuberculosis by adding Deltyba™ to background regimens in Germany. Respir Med. 2015;109(5):632–41.

    Article  PubMed  Google Scholar 

  27. Blair HA, Scott LJ. Delamanid: a review of its use in patients with multidrug-resistant tuberculosis. Drugs. 2015;75(1):91–100.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The review was updated from Drugs 2015;75(1):91–100 [27], and was reviewed by: N. Cebotarenco, Coalition for Rational and Safe Use of Medicines (CoRSUM), Chişinău, Republic of Moldova; I. D. Olaru, Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany, S. Saluja, Saran Ashram Hospital, Dayalbagh, Agra, India; J-P. Zellweger, Swiss Lung Association, Berne, Switzerland. During the peer review process, the manufacturer of delamanid was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Springer, Private Bag 65901, Mairangi Bay, 0754, Auckland, New Zealand

    Katherine A. Lyseng-Williamson, Hannah A. Blair & Lesley J. Scott

Authors
  1. Katherine A. Lyseng-Williamson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hannah A. Blair
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katherine A. Lyseng-Williamson.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

K A. Lyseng-Williamson, H. A. Blair and L. J. Scott are salaried employees of Adis/Springer, are responsible for the article content and declare no relevant conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lyseng-Williamson, K.A., Blair, H.A. & Scott, L.J. Delamanid in multidrug-resistant tuberculosis: a guide to its use in the EU. Drugs Ther Perspect 31, 378–384 (2015). https://doi.org/10.1007/s40267-015-0251-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-015-0251-8

Keywords

Search

Navigation